Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04195932 · ClinicalTrials.gov registry record · NA

Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease

A NA study of Heart Diseases, sponsored by East Tennessee State University.

Completed
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT04195932 is a NA study of Heart Diseases that has completed, run by East Tennessee State University. The registered enrollment target is 52 participants, below the 5,532-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04195932, a NA study of Heart Diseases, has completed, sponsored by East Tennessee State University.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

A before and after study involving 43 adult subjects at risk of having ischemic heart disease. Subjects underwent 6 months of supervised moderate intensity aerobic and resistive exercise training. Blood samples were obtained at entry and at 6 months for measurement of complement (C3), CRP, blood lipid levels, lymphocyte phenotypes, and for the isolation, culture, and measurement of the spontaneous and phytohemagglutinin-induced secretion of proatherogenic and antiatherogenic cytokines by their peripheral blood mononuclear cells (PBMC).

Conditions Studied

Interventions

  • OTHER Exercise training

Study Locations (1)

Tennessee

  • James H. Quillen College of Medicine - Johnson City

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 1996-12
Est. Completion 1998-05
Phase NA

Sponsor

East Tennessee State University

16 total trials

What the Registry Record Tells You About NCT04195932

The ClinicalTrials.gov registry entry for NCT04195932 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,532-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The listed sponsor is East Tennessee State University, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which Exercise training is the first listed.

NCT04195932 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT04195932 about?

NCT04195932 is a clinical study titled "Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease". A before and after study involving 43 adult subjects at risk of having ischemic heart disease. Subjects underwent 6 months of supervised moderate intensity aerobic and resistive exercise training. Blood samples were obtained at entry and at 6 months for measurement of complement (C3), CRP, blood lip...

What is the current status of trial NCT04195932?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 1996-12. Estimated completion is 1998-05.

What conditions does trial NCT04195932 study?

This clinical trial studies the following conditions: Heart Diseases.

What interventions are being tested in trial NCT04195932?

The interventions under investigation include: Exercise training (OTHER).

Who is sponsoring clinical trial NCT04195932?

This trial is sponsored by East Tennessee State University, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04195932 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.